Publication: Evaluation of polyesteramide (PEA) and polyester (PLGA) microspheres as intravitreal drug delivery systems in albino rats
Loading...
Official URL
Full text at PDC
Publication Date
2017-04
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Elsevier
Citations
Exportar
Abstract
Purpose: To study the suitability of injectable microspheres based on poly(ester amide) (PEA) or poly lactic-co-glycolic acid (PLGA) as potential vehicles for intravitreal drug delivery in rat eyes. Dexamethasone loaded PEA microspheres (PEA+DEX) were also evaluated.
Methods: Forty male Sprague Dawley rats were divided into four groups that received different intravitreally injected microspheres: PEA group (n=12); PLGA group (n=12); PEA+DEX group (n=8); and control group (no injection, n=8). Electroretinography (ERG), fundus autofluorescence (FAF), and spectral domain optical coherence tomography (sdOCT) were performed at baseline, weeks 1 and 2, and months 1, 2, and 3 after intravitreal injection. Eyes were histologically examined using light microscopy and transmission electron microscopy at the end of the in vivo study.
Results: There were no statistically significant changes in ERG among the groups. Abnormal FAF pattern and abnormal deposits in OCT were observed after injection but almost completely disappeared between week 2 and month 3 in all injected groups. GFAP staining showed that Müller glia cell activation was most pronounced in PLGA-injected eyes. Increased cell death was not observed by TUNEL staining at month 1. In electron microscopy at month 3, the remnants of microparticles were found in the retinal cells of all injected groups, and loss of plasma membrane was seen in the PLGA group.
Conclusions: Although morphological changes such as mild glial activation and material remnants were observed histologically 1 month and 3 months after injection in all injected groups, minor cell damage was noted only in the PLGA group at 3 months after injection. No evidence of functional abnormality relative to untreated eyes could be detected by ERG 3 months after injection in all groups. Changes observed in in vivo imaging such as OCT and FAF disappeared after 3 months in almost all cases.
Description
UCM subjects
Unesco subjects
Keywords
Citation
1. Herrero-Vanrell R, Bravo-Osuna I, Andrés-Guerrero V, Vicario-de-la-Torre M,
Molina-Martínez IT.
The potential of using biodegradable microspheres in retinal diseases and other
intraocular pathologies.
Prog Retin Eye Res. 2014;42:27-43.
2. Yihan Xu, Chang-Soo Kim, David M. Saylor and Donghun Koo
Polymer degradation and drug delivery in PLGA-based drug–polymer applications: A
review of experiments and theories.
Article first published online: 21 APR 2016 | DOI: 10.1002/jbm.b.33648
3. Tan DT, Chee SP, Lim L, Theng J, Van Ede M.
Randomized clinical trial of Surodex steroid drug delivery system for cataract surgery:
anterior versus posterior placement of two Surodex in the eye. Ophthalmology.
2001;108:2172-2181.
4. Haller JA, Bandello F, Belfort R Jr, et al.
Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients
with macular edema due to retinal vein occlusion.
Ophthalmology. 2010;117:1134-1146.e3.
5. Lowder C, Belfort R Jr, Lightman S, et al.
Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis.
Arch Ophthalmol. 2011;129:545-553.
6. Srour M, Querques G, Leveziel N, et al.
Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa.
Graefes Arch Clin Exp Ophthalmol. 2013;251:1501-1506.
7. Campochiaro PA, Brown DM, Pearson A, et al.
Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least
3 years in patients with diabetic macular edema.
Ophthalmology. 2012;119:2125-2132.
8. Calvo P, Ferreras A, Al Adel F, Wang Y, Brent MH.
Dexamethasone intravitreal implant as adjunct therapy for patients with wet agerelated
macular degeneration with incomplete response to ranibizumab.
Br J Ophthalmol. 2015;99:723-726.
9. Kunou N, Ogura Y, Yasukawa T, et al.
Long-term sustained release of ganciclovir from biodegradable scleral implant for the
treatment of cytomegalovirus retinitis.
J Control Release. 2000;68:263-271.
10. Sun H, Meng F, Dias AA, Hendriks M, Feijen J, Zhong Z
α-Amino acid containing degradable polymers as functional biomaterials: rational
design, synthetic pathway, and biomedical applications.
Biomacromolecules. 2011 Jun 13;12(6):1937-55. doi: 10.1021/bm200043u. Epub
2011 Apr 26.
11. Katsarava R, Beridze Z, Arabuli N, et al.
Amino acid-based bioanalogous polymers. Synthesis, and study of regular poly(ester
amide)s based on bis(α-amino acid) α,ω-alkylene diesters, and aliphatic dicarboxylic
acids.
J Polym Sci, Part A: Polym Chem. 1999:37;391-407.
12. Jiaolong Lv,, Huanli Sun, Yan Zou, Fenghua Meng, Aylvin A. Dias, Marc Hendriks,
Jan Feijen and Zhiyuan Zhong
Reductively degradable α-amino acid-based poly(ester amide)-graft-galactose
copolymers: facile synthesis, self-assembly, and hepatoma-targeting doxorubicin
delivery.
Biomater. Sci., 2015,3, 1134-1146, DOI: 10.1039/C4BM00436A, Received 16 Dec
2014, Accepted 19 Mar 2015, First published online 08 Apr 2015
13. Nicolas J, Mura S, Brambilla D, et al.
Functionalization strategies and biomedical applications of targeted
biodegradable/biocompatible polymer-based nanocarriers for drug delivery.
Chem Soc Rev. 2013:42;1147-1235.
14. Tsitlanadze G1, Machaidze M, Kviria T, Djavakhishvili N, Chu CC, Katsarava R
Biodegradation of amino-acid-based poly(ester amide)s: in vitro weight loss and
preliminary in vivo studies.
J Biomater Sci Polym Ed. 2004;15(1):1-24.
15. Pang X, Chu CC.
Synthesis, characterization and biodegradation of functionalized amino acid-based
poly(ester amide)s.
Biomaterials. 2010:31;3745-3754.
16. Kropp M, Morawa K-M, Mihov G, et al.
Biocompatibility of Poly(ester amide) (PEA) Microfibrils in Ocular Tissues.
Polymers. 2014:6;243-260.
17. Webster M1, Harding S, McClean D, Jaffe W, Ormiston J, Aitken A, Watson T.
First-in-human evaluation of a sirolimus-eluting coronary stent on an integrated
delivery system: the DIRECT study.
EuroIntervention. 2013 May 20;9(1):46-53. doi: 10.4244/EIJV9I1A8.
18. Brunner A, Mäder K, Göpferich A.
pH and osmotic pressure inside biodegradable microspheres during erosion.
Pharm Res. 1999:16;847-853
19. Andrés-Guerrero V, Zong M, Ramsay E, et al.
Novel biodegradable polyesteramide microspheres for controlled drug delivery in
Ophthalmology.
J Control Release. 2015;211: 105-117
20. Freitas S, Merkle H, Gander B.
Microencapsulation by solvent extraction/evaporation: reviewing the state of the art
of microsphere preparation process technology.
J Control Release. 2005:102;313-332.
21. Arabuli, N., Tsitlanadze, G., Edilashvili, L., Kharadze, D., Goguadze, T., Beridze,
V., Gomurashvili, Z., Katsarava, R.
Heterochain polymers based on natural amino acids. Synthesis and enzymatic
hydrolysis of regular poly(ester amide)s based on bis(L-phenylalanine) apalkylene
diesters and adipic acid.
Macromol. Chem. Phys. 1994, 195, 2279–2289.
22. Ghaffar A., Draaisma G., Mihov G., Dias A., Schoenmakers P., Van Der Wal Sj.,
Monitoring the in vitro enzyme-mediated degradation of degradable poly(ester amide)
for controlled drug delivery by LC-ToF-MS.
Biomacromolecules. 2011 Sep 12;12(9):3243-51.
23. Tsitlanadze G, Kviria T, Katsarava R
In vitro enzymatic biodegradation of amino acid based poly(ester amide)s
biomaterials
Journal of Material science in Medicine 15 (2004) 185-190
24. Strasser T, Wilke R, Messias A, Zrenner E.
Erg explorer: a software for post-processing, analysing, and reporting of
electrophysiological data.
Acta Ophthalmologica, 2008:86(s243);0.
25. Strasser T, Peters T, Jagle H, Zrenner E, Wilke R.
An integrated domain specific language for post-processing and visualizing
electrophysiological signals in Java.
Conf Proc IEEE Eng Med Biol Soc. 2010;2010:4687-4690.
26. Tröger E.
Assessment of Morphology and Function in Retinal Degeneration by Multi-Modal
Mapping.
1st ed. Aachen, Germany: Shaker verlag; 2011:48-55.
27. Dhillon H1, Kalra SP, Prima V, Zolotukhin S, Scarpace PJ, Moldawer LL,
Muzyczka N, Kalra PS.
Central leptin gene therapy suppresses body weight gain, adiposity and serum
insulin without affecting food consumption in normal rats: a long-term study.
Regul Pept. 2001 Jun 15;99(2-3):69-77.
28. Ferry, E. L. (1913)
The rate of growth of the albino rat.
Anat. Rec., 7: 433–441. doi: 10.1002/ar.1090071203
29. Frederick T. Fraunfelder,Frederick W. Fraunfelder Jr.,Wiley A. Chambers
Clinical Ocular Toxicology: Drug-Induced Ocular Side Effects.
ISBN-13: 978-0323319843
30. Gong A, Ma X, Xiang L, et al.
Improved double emulsion technology for fabricating autofluorescent microcapsules
as novel ultrasonic/fluorescent dual-modality contrast agents.
Colloids Surf B Biointerfaces. 2014;116:561-567.
31. Shearer H, Ellis MJ, Perera SP, Chaudhuri JB.
Effects of common sterilization methods on the structure and properties of poly(D,L
lactic-co-glycolic acid) scaffolds.
Tissue Eng. 2006;12:2717-2727.
32. Bringmann A, Pannicke T, Grosche J, et al.
Müller cells in the healthy and diseased retina.
Prog Retin Eye Res. 2006;25:397-424.
33. Seitz R, Tamm ER.
Müller cells and microglia of the mouse eye react throughout the entire retina in
response to the procedure of an intravitreal injection.
Adv Exp Med Bio. 2014;801:347-53.
34. Bringmann A, Pannicke T, Moll V, et al.
Upregulation of P2X7 receptor currents in Müller glial cells during proliferative
vitreoretinopathy.
Invest Ophthalmol Vis Sci. 2001;42:860-867.
35. Lewis GP, Fisher SK.
Up-regulation of glial fibrillary acidic protein in response to retinal injury: its potential
role in glial remodeling and a comparison to vimentin expression.
Int Rev Cytol. 2003;230:263-290.
36. Bringmann A, Pannnicke T, Biedermann B, et al.
Role of retinal glial cells in neurotransmitter uptake and metabolism.
Neurochem Int. 2009;53:143-160.
37. Sofroniew MV.
Reactive astrocytes in neural repair and protection.
Neuroscientist. 2005;11:400-407.
38. Lewis GP, Guerin CJ, Anderson DH, Matsumoto B, Fisher SK.
Rapid changes in the expression of glial cell proteins caused by experimental retinal
detachment.
39. Bringmann A, Reichenbach A, Wiedemann P.
Pathomechanisms of cystoid macular edema.
Ophthalmic Res. 2004;36:241-249.
40. Bringmann A, Francke M, Pannicke T, et al.
Role of glial K(+) channels in ontogeny and gliosis: a hypothesis based upon studies
on Müller cells.
Glia. 2000;29:35-44
41. Tenckhoff S, Hollborn M, Kohen L, et al.
Diversity of aquaporin mRNA expressed by rat and human retinas.
Neuroreport. 2005;16:53-56.